Abstract We describe the occurrence of a giant squamous cell carcinoma in a patient receiving vemurafenib for the treatment of late melanoma mestastases. Although the development of keratoacanthomas and squamous cell carcinomas (SCC) has been described during vemurafenib therapy, most of the reported cases are treated with surgical excision. In the present case, SCC regressed after drug withdrawal.
We describe the occurrence of a giant squamous cell carcinoma in a patient receiving vemurafenib for the treatment of late melanoma mestastases. Although the development of keratoacanthomas and squamous cell carcinomas (SCC) has been described during vemurafenib therapy, most of the reported cases are treated with surgical excision. In the present case, SCC regressed after drug withdrawal.
Dika, E., Patrizi, A., Altimari, A., Fiorentino, M., La Placa, M., Gruppioni, E., et al. (2015). Virologic and genetic evaluation of vemurafenib-induced skin cancers. CUTANEOUS AND OCULAR TOXICOLOGY, 34(3), 251-253 [10.3109/15569527.2014.949345].
Virologic and genetic evaluation of vemurafenib-induced skin cancers
DIKA, EMI;PATRIZI, ANNALISA;ALTIMARI, ANNALISA;FIORENTINO, MICHELANGELO;LA PLACA, MICHELANGELO;GRUPPIONI, ELISA;VENTUROLI, SIMONA;VACCARI, SABINA;MELOTTI, BARBARA;PIRACCINI, BIANCA MARIA;FANTI, PIER ALESSANDRO
2015
Abstract
We describe the occurrence of a giant squamous cell carcinoma in a patient receiving vemurafenib for the treatment of late melanoma mestastases. Although the development of keratoacanthomas and squamous cell carcinomas (SCC) has been described during vemurafenib therapy, most of the reported cases are treated with surgical excision. In the present case, SCC regressed after drug withdrawal.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
